IVAX Insider Trading Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: harkenman who wrote ()	6/25/1999 8:29:00 AM
From: kendall harmon	Read Replies (2) of 756

IVX-a positive article in business week. Business Week's Inside Wall Street -- Highlights Thursday June 24, 1999 (6:16 pm ET) Business Week's Inside Wall Street -- Highlights NEW YORK, Jun. 24 (Standard & Poor's) - The following are highlights from the Inside Wall Street column in the latest issue of Business Week. The full stories will appear on S&P Personal Wealth Friday morning. IVAX Corp David Saks of Gruntal says IVAX Corp (IVX) is a revamped company. He says IVX has sold off assets, reenergized profits, and come out with a pipeline of proprietary drugs including delivery technologies for cancer and asthma remedies. He says the shares have yet to reflect the company's "new positive attributes." He thinks IVAX will hit $18 in one year and $40 in three years. He says IVX could be attractive for a possible takeover. He sees sales jumping to $1 billion by 2001. He sees $0.40 1999 EPS, $0.60 2000 EPS, and $0.85 2001. Harvey Eisen of Bedford Oak Associates says after two failed merger attempts, the company has become an even more attractive target.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next